A

Acrivon Therapeutics Inc
NASDAQ:ACRV

Watchlist Manager
Acrivon Therapeutics Inc
NASDAQ:ACRV
Watchlist
Price: 2.29 USD -6.91% Market Closed
Market Cap: 72.3m USD

Acrivon Therapeutics Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Acrivon Therapeutics Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
A
Acrivon Therapeutics Inc
NASDAQ:ACRV
Cash from Operating Activities
-$65.7m
CAGR 3-Years
-67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Acrivon Therapeutics Inc
Glance View

Market Cap
72.2m USD
Industry
Biotechnology

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2022-11-15. The firm's lead clinical candidate ACR-368, is a selective small molecule inhibitor targeting CHK1/2. CHK1/2 are regulators of the cell cycle and of DNA Damage Response (DDR). The company also has two preclinical drug programs designed to take advantage of its AP3 platform and the ability to predict tumor sensitivity based on custom OncoSignature tests. Its AP3 platform is based on its proprietary approach developed to enable treatment of the patients who are most likely to respond to any particular drug candidate based on dependency in the tumor on the upregulated specific biochemical pathways that each drug modulates. The firm's OncoSignature tests are automated, quantitative proteomic tissue imaging tests applied to pre-treatment tumor biopsies as a companion diagnostic (CDx), to select and treat the patients predicted to benefit from the drug candidate.

ACRV Intrinsic Value
Not Available
A

See Also

What is Acrivon Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-65.7m USD

Based on the financial report for Dec 31, 2024, Acrivon Therapeutics Inc's Cash from Operating Activities amounts to -65.7m USD.

What is Acrivon Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-67%

Over the last year, the Cash from Operating Activities growth was -54%. The average annual Cash from Operating Activities growth rates for Acrivon Therapeutics Inc have been -67% over the past three years .

Back to Top